FDA asks Citius for en­hanced prod­uct test­ing in CRL for non-Hodgkin lym­phoma drug Lym­phir

The FDA hit Citius Phar­ma­ceu­ti­cals with a com­plete re­sponse let­ter (CRL) for its treat­ment of re­lapsed or re­frac­to­ry cu­ta­neous T-cell lym­phoma (CT­CL), a rare form …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER